Vertex Pharmaceuticals Incorporated
VRTX - NASDAQ - $423.92 ▼ -%0.81
-
Earnings Mon 4 May
Note: this preview was published before the 2026-05-04 earnings report. Results have since been released — verify against the latest filings.

Vertex opens the
books on Monday evening.

15 analysts' median target is $558[FMP target], stock is $424, +31.6% upside potential. After Q4 +-1.6% EPS beat[FMP earnings], the stock moved +5.7%.

↓ summary below
Quick Take - in 40 seconds
B+
BUY Council 4/6 - Moonshot 66

B+ = MoonshotScore 66[9-pillar formula] + Council 4/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $3.0B[FMP est], EPS $4.23[FMP est]. 0 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$4.23 EPS Estimate Last year $5.03 - +4% YoY YoY
0 Beat Streak Expectations beaten consecutively for the last 0 quarters

Q4 EPS +-1.6% beat[FMP] but the stock +5.7% D+1[FMP D+1]. Charles Wagner promised $149.4M CapEx + a sequential decline in Q4 during the Q4 earnings call[Charles Wagner capex transcript].

Watchlist

5 metrics stand out this quarter.

19.5% Expectation / Guide

Effective Tax Rate Guidance

effective_tax_rate_guidance

Vertex anticipates its non-GAAP effective tax rate to be in the range of 19.5% to 20.5% for 2026.

"We anticipate our non-GAAP effective tax rate to be in the range of 19.5% to 20.5% for 2026 as we do not expect a repeat of the onetime tax benefits we experienced in 2025."

- Charles Wagner, Chief Operating Officer and Chief Financial Officer - Q4 FY25 Earnings Call - February 12, 2026
8% Investor Focus

2026 Revenue Growth

2026_revenue_growth

Vertex anticipates total company revenue growth of 8% to 9% in 2026.

"We expect full year 2026 total company revenue to be in the range of $12.95 billion to $13.1 billion, representing 8% to 9% growth versus the prior year."

- Charles Wagner, Chief Operating Officer and Chief Financial Officer - Q4 FY25 Earnings Call - February 12, 2026
$5.65 billion Expectation / Guide

Operating Expense Guidance

operating_expense_guidance

Vertex anticipates combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion for 2026.

"Additionally, we expect combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as we continue to invest in our late-stage clinical pipeline and commercial buildouts in support of new launches and revenue diversification, particularly for JOURNAVX in acute pain and for renal."

- Charles Wagner, Chief Operating Officer and Chief Financial Officer - Q4 FY25 Earnings Call - February 12, 2026
$500 million Investor Focus

Non CF Revenue Contribution

non_CF_revenue_contribution

Vertex expects a $500 million or greater revenue contribution from non-CF products in 2026.

"This outlook anticipates continued solid performance from our CF franchise and a $500 million or greater revenue contribution from non-CF products, including greater volumes of patient infusions for CASGEVY and a ramp of JOURNAVX prescriptions."

- Charles Wagner, Chief Operating Officer and Chief Financial Officer - Q4 FY25 Earnings Call - February 12, 2026
550,000 Investor Focus

Journavx Prescription Growth

journavx_prescription_growth

Vertex expects JOURNAVX prescriptions to more than triple in 2026 compared to 2025.

"In 2026, we expect to more than triple the number of JOURNAVX prescriptions compared to approximately 550,000 written in 2025."

- Duncan J. McKechnie, Chief Commercial Officer - Q4 FY25 Earnings Call - February 12, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 66 / 100

9-pillar methodology. Revenue Growth and Gross Margin strong. R&D Intensity weak.

How is it calculated? ->
Revenue Growth8.0Q4 vs Q1: fast growth (+16.5%)
Gross Margin9.0Q4: very high margin (85.6%, software/cloud territory)
Operating Leverage4.0op margin very strong (40.3%, scale leverage)
Cash Runway10.0FCF very strong ($0.3B, 2.3x CapEx)
R&D Intensity3.0very high R&D (32.9%, margin pressure risk)
Price Momentum4.0RSI 38.7 weak momentum, 50d below
News Sentiment8.0strong buy consensus (81%)
Council Score 4 / 6 Bullish

6 investor frameworks. 4 bullish (Ray Dalio, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +31.6%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 39
Klarman value - target upside +31.6%
Buffett quality - ROE score 5/5
Munger valuation - target upside +31.6%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
38.7 RSI 38.7 weak momentum, 50d below
MACD
-6.50 price below 50d - resistance dominant
50d MA
$454 stock 6.5% below - short-term resistance
200d MA
$436 stock 2.8% below - long-term pressure
Volume (10d)
-13% decrease - low participation
Resistance
$558
Analyst median target - upgrade trigger if broken
Current
$424
Pre-earnings position
Support
$371
Invalidation - close below this is a technical breakdown
Pattern
Range
$371-$558 band - earnings breakout/breakdown trigger

Past Performance

Vertex's last 8 quarters: 0 consecutive beats.

MISS
Q1 FY25
$4.06 vs $4.25 est - -10.0%
BEAT
Q2 FY25
$4.52 vs $4.29 est - -20.6%
BEAT
Q3 FY25
$4.80 vs $4.57 est - -1.0%
MISS
Q4 FY25
$5.03 vs $5.11 est - +5.7%

Q4 (February 12, 2026): EPS $5.03 vs $5.11 est[FMP], +-1.6% beat. D+1 movement: +5.7%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $4.10 (no guidance)

Q4: EPS $5.03 vs $5.11 beat[FMP], stock +5.7% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

CapEx shock

Q4 CapEx $149.4M[FMP cashflow]. Q4 op margin 40.3%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $4.23 + CapEx discipline
Threshold: EPS > $4.23[FMP est].
Target: Break above median target $558[FMP target]; high target $612[FMP] upper bound.
Scenario B - In-Line
EPS approx $4.23 + CapEx < $149.4M
Threshold: EPS approx $4.23[FMP est], Q4 CapEx < $149.4M[FMP].
Target: Consolidation in the band between current $424[FMP] and median $558[FMP].
Scenario C - Miss
EPS < $4.10 or CapEx >= $149.4M
Threshold: EPS < $4.10[FMP estx0.97].
Target: Current $424 below SMA200 $436[FMP], if rejection continues, $371[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 15 analysts say?

Wall Street Consensus
$558
12-month median target price (+31.6% upside potential)
26
BUY
5
HOLD
1
SELL
Risk Management
$371
Invalidation level - critical support threshold
$454 - 50-day MA (below, -6.5%)
$436 - 200-day MA (below, -2.8%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - VRTX Q4 FY26
B+

You read it in 5 minutes. When the numbers come out on Monday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Monday evening. The framework is ready on this page: Q4 EPS threshold $4.23[FMP], CapEx threshold "below $149.4M"[Charles Wagner]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days VRTX dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

May 4, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
May 5, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Jun 18, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Aug 4, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the VRTX earnings preview cover?

This VRTX (VRTX) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in VRTX earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.